Published in Int J Pharm on June 20, 2002
Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev (2013) 3.44
Nanoprobes with near-infrared persistent luminescence for in vivo imaging. Proc Natl Acad Sci U S A (2007) 2.49
Geometry and surface characteristics of gold nanoparticles influence their biodistribution and uptake by macrophages. Eur J Pharm Biopharm (2010) 1.67
Factors controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Control Release (2013) 1.64
Plasma clearance of bacteriophage Qbeta particles as a function of surface charge. J Am Chem Soc (2008) 1.41
Drug delivery trends in clinical trials and translational medicine: challenges and opportunities in the delivery of nucleic acid-based therapeutics. J Pharm Sci (2011) 1.24
Influence of cationic lipid composition on gene silencing properties of lipid nanoparticle formulations of siRNA in antigen-presenting cells. Mol Ther (2011) 1.23
Role of surface charge and oxidative stress in cytotoxicity of organic monolayer-coated silicon nanoparticles towards macrophage NR8383 cells. Part Fibre Toxicol (2010) 1.18
Cholesterol derivatives based charged liposomes for doxorubicin delivery: preparation, in vitro and in vivo characterization. Theranostics (2012) 1.13
Poly(omega-pentadecalactone-co-butylene-co-succinate) nanoparticles as biodegradable carriers for camptothecin delivery. Biomaterials (2009) 1.12
Activation of latent HIV using drug-loaded nanoparticles. PLoS One (2011) 1.10
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Etoposide-incorporated tripalmitin nanoparticles with different surface charge: formulation, characterization, radiolabeling, and biodistribution studies. AAPS J (2004) 0.98
Comparative study of the in vitro and in vivo characteristics of cationic and neutral liposomes. Int J Nanomedicine (2011) 0.95
Hyaluronan polymer length, grafting density, and surface poly(ethylene glycol) coating influence in vivo circulation and tumor targeting of hyaluronan-grafted liposomes. ACS Nano (2014) 0.92
PEGylation of a factor VIII-phosphatidylinositol complex: pharmacokinetics and immunogenicity in hemophilia A mice. AAPS J (2011) 0.87
Surface-modified HK:siRNA nanoplexes with enhanced pharmacokinetics and tumor growth inhibition. Biomacromolecules (2013) 0.86
Internalization of paramagnetic phosphatidylserine-containing liposomes by macrophages. J Nanobiotechnology (2012) 0.84
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come. Pharmacol Rev (2016) 0.84
Effect of charged and non-ionic membrane additives on physicochemical properties and stability of niosomes. AAPS PharmSciTech (2008) 0.83
Nano-advantage in enhanced drug delivery with biodegradable nanoparticles: contribution of reduced clearance. Drug Metab Dispos (2012) 0.82
Development of EGFR-targeted nanoemulsion for imaging and novel platinum therapy of ovarian cancer. Pharm Res (2014) 0.81
Synthesis, characterization, and evaluation of a novel amphiphilic polymer RGD-PEG-Chol for target drug delivery system. ScientificWorldJournal (2014) 0.80
Formulation development of a novel targeted theranostic nanoemulsion of docetaxel to overcome multidrug resistance in ovarian cancer. Drug Deliv (2014) 0.78
Illuminating the physiology of extracellular vesicles. Stem Cell Res Ther (2016) 0.78
Temporal assessment of nanoparticle accumulation after experimental brain injury: Effect of particle size. Sci Rep (2016) 0.76
Nanoparticle Formulation to Improve the Efficacy of Radiation Therapy Against Radiation-resistant Leukemia. EBioMedicine (2015) 0.76
A brief perspective on the diverging theories of lymphatic targeting with colloids. Int J Nanomedicine (2016) 0.75
Efficacy of Liposomal Monensin on the Enhancement of the Antitumour Activity of Liposomal Ricin in Human Epidermoid Carcinoma (KB) Cells. Indian J Pharm Sci (2013) 0.75
DAFODIL: A novel liposome-encapsulated synergistic combination of doxorubicin and 5FU for low dose chemotherapy. J Control Release (2016) 0.75
Delivery of antisense oligonucleotides using poly(alkylene oxide)-poly(propylacrylic acid) graft copolymers in conjunction with cationic liposomes. J Control Release (2014) 0.75
Effect of pegylated phosphatidylserine-containing liposomes in experimental chronic arthritis. BMC Pharmacol Toxicol (2015) 0.75
Stearylamine Liposomal Delivery of Monensin in Combination with Free Artemisinin Eliminates Blood Stages of Plasmodium falciparum in Culture and P. berghei Infection in Murine Malaria. Antimicrob Agents Chemother (2015) 0.75
Porous Silicon and Polymer Nanocomposites for Delivery of Peptide Nucleic Acids as Anti-MicroRNA Therapies. Adv Mater (2016) 0.75
The effects of nanoparticle drug loading on the pharmacokinetics of anticancer agents. Nanomedicine (Lond) (2015) 0.75
Drug-loadable Mesoporous Bioactive Glass Nanospheres: Biodistribution, Clearance, BRL Cellular Location and Systemic Risk Assessment via (45)Ca Labelling and Histological Analysis. Sci Rep (2016) 0.75
Theranostic Liposome-Nanoparticle Hybrids for Drug Delivery and Bioimaging. Int J Mol Sci (2017) 0.75
Quantum dots spectrally distinguish multiple species within the tumor milieu in vivo. Nat Med (2005) 3.19
Peptide and protein drug delivery to and into tumors: challenges and solutions. Drug Discov Today (2003) 2.72
Immunomicelles: targeted pharmaceutical carriers for poorly soluble drugs. Proc Natl Acad Sci U S A (2003) 2.28
Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev (2004) 2.13
Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev (2004) 2.12
Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res (2002) 2.09
Cell transfection in vitro and in vivo with nontoxic TAT peptide-liposome-DNA complexes. Proc Natl Acad Sci U S A (2003) 2.05
Matrix metalloprotease 2-responsive multifunctional liposomal nanocarrier for enhanced tumor targeting. ACS Nano (2012) 1.86
Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody. J Control Release (2004) 1.80
Cell-penetrating peptides: breaking through to the other side. Trends Mol Med (2012) 1.68
Polyethylene glycol-diacyllipid micelles demonstrate increased acculumation in subcutaneous tumors in mice. Pharm Res (2002) 1.60
Lipid modified triblock PAMAM-based nanocarriers for siRNA drug co-delivery. Biomaterials (2012) 1.59
Design, synthesis, and characterization of pH-sensitive PEG-PE conjugates for stimuli-sensitive pharmaceutical nanocarriers: the effect of substitutes at the hydrazone linkage on the ph stability of PEG-PE conjugates. Bioconjug Chem (2007) 1.43
Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res (2009) 1.35
Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood (2004) 1.31
In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res (2004) 1.31
Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem (2006) 1.29
Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target (2007) 1.27
Multifunctional PEGylated 2C5-immunoliposomes containing pH-sensitive bonds and TAT peptide for enhanced tumor cell internalization and cytotoxicity. J Control Release (2011) 1.25
Self-assembling micelle-like nanoparticles based on phospholipid-polyethyleneimine conjugates for systemic gene delivery. J Control Release (2008) 1.22
Enhanced binding and killing of target tumor cells by drug-loaded liposomes modified with tumor-specific phage fusion coat protein. Nanomedicine (Lond) (2010) 1.21
Organelle-targeted nanocarriers: specific delivery of liposomal ceramide to mitochondria enhances its cytotoxicity in vitro and in vivo. Nano Lett (2008) 1.19
Radiofrequency thermal ablation sharply increases intratumoral liposomal doxorubicin accumulation and tumor coagulation. Cancer Res (2003) 1.19
Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release (2004) 1.19
Liposomes targeted by fusion phage proteins. Nanomedicine (2008) 1.19
Polyethylene glycol-phosphatidylethanolamine conjugate (PEG-PE)-based mixed micelles: some properties, loading with paclitaxel, and modulation of P-glycoprotein-mediated efflux. Int J Pharm (2006) 1.17
Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol Pharm (2010) 1.17
Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging (2006) 1.17
Combined radiofrequency ablation and adjuvant liposomal chemotherapy: effect of chemotherapeutic agent, nanoparticle size, and circulation time. J Vasc Interv Radiol (2005) 1.16
Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev (2013) 1.14
P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells. Nanomedicine (Lond) (2012) 1.14
Percutaneous tumor ablation: increased necrosis with combined radio-frequency ablation and intravenous liposomal doxorubicin in a rat breast tumor model. Radiology (2002) 1.14
Enhanced cytotoxicity of monoclonal anticancer antibody 2C5-modified doxorubicin-loaded PEGylated liposomes against various tumor cell lines. Eur J Pharm Sci (2007) 1.14
Design of multifunctional non-viral gene vectors to overcome physiological barriers: dilemmas and strategies. Int J Pharm (2011) 1.13
Polymeric micelles for delivery of poorly soluble drugs: preparation and anticancer activity in vitro of paclitaxel incorporated into mixed micelles based on poly(ethylene glycol)-lipid conjugate and positively charged lipids. J Drug Target (2005) 1.12
siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene. J Control Release (2006) 1.12
Reversal of multidrug resistance by co-delivery of tariquidar (XR9576) and paclitaxel using long-circulating liposomes. Int J Pharm (2011) 1.12
Radio-frequency ablation increases intratumoral liposomal doxorubicin accumulation in a rat breast tumor model. Radiology (2002) 1.11
ATP-loaded liposomes effectively protect the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res (2005) 1.10
Polyethyleneimine-lipid conjugate-based pH-sensitive micellar carrier for gene delivery. Biomaterials (2012) 1.09
Recent developments in lipid-based pharmaceutical nanocarriers. Front Biosci (Landmark Ed) (2011) 1.09
"Smart" drug carriers: PEGylated TATp-modified pH-sensitive liposomes. J Liposome Res (2007) 1.09
pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials (2012) 1.08
Do liposomal apoptotic enhancers increase tumor coagulation and end-point survival in percutaneous radiofrequency ablation of tumors in a rat tumor model? Radiology (2010) 1.07
Liposomes loaded with paclitaxel and modified with novel triphenylphosphonium-PEG-PE conjugate possess low toxicity, target mitochondria and demonstrate enhanced antitumor effects in vitro and in vivo. J Control Release (2012) 1.06
Recent trends in multifunctional liposomal nanocarriers for enhanced tumor targeting. J Drug Deliv (2013) 1.06
Antibody-maytansinoid conjugates for the treatment of myeloma. MAbs (2009) 1.05
Antinucleosome antibody-modified liposomes and lipid-core micelles for tumor-targeted delivery of therapeutic and diagnostic agents. J Liposome Res (2007) 1.05
PEG-PE micelles loaded with paclitaxel and surface-modified by a PBR-ligand: synergistic anticancer effect. Mol Pharm (2009) 1.05
Synergy of photoacoustic and fluorescence flow cytometry of circulating cells with negative and positive contrasts. J Biophotonics (2012) 1.05
Current trends in liposome research. Methods Mol Biol (2010) 1.05
Poly(malic acid) nanoconjugates containing various antibodies and oligonucleotides for multitargeting drug delivery. Nanomedicine (Lond) (2008) 1.04
Accumulation and toxicity of antibody-targeted doxorubicin-loaded PEG-PE micelles in ovarian cancer cell spheroid model. J Control Release (2012) 1.04
Challenges in development of targeted liposomal therapeutics. AAPS J (2012) 1.03
Tumor-specific antibody-mediated targeted delivery of Doxil reduces the manifestation of auricular erythema side effect in mice. Int J Pharm (2008) 1.03
Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery. J Control Release (2003) 1.03
Combination radiofrequency ablation with intratumoral liposomal doxorubicin: effect on drug accumulation and coagulation in multiple tissues and tumor types in animals. Radiology (2005) 1.02
Mixed PEG-PE/vitamin E tumor-targeted immunomicelles as carriers for poorly soluble anti-cancer drugs: improved drug solubilization and enhanced in vitro cytotoxicity. Eur J Pharm Biopharm (2008) 1.02
Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem (2011) 1.01
Monoclonal antibody 2C5-modified doxorubicin-loaded liposomes with significantly enhanced therapeutic activity against intracranial human brain U-87 MG tumor xenografts in nude mice. Cancer Immunol Immunother (2007) 1.00
Landscape phage fusion protein-mediated targeting of nanomedicines enhances their prostate tumor cell association and cytotoxic efficiency. Nanomedicine (2010) 1.00
Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy. Mol Pharm (2009) 1.00
Cancer cell spheroids as a model to evaluate chemotherapy protocols. Cancer Biol Ther (2012) 0.99
Delivery of siRNA into breast cancer cells via phage fusion protein-targeted liposomes. Nanomedicine (2010) 0.99
Enhanced anticancer activity of nanopreparation containing an MMP2-sensitive PEG-drug conjugate and cell-penetrating moiety. Proc Natl Acad Sci U S A (2013) 0.99
Environment-responsive multifunctional liposomes. Methods Mol Biol (2010) 0.99
Cytoplasmic delivery of liposomes into MCF-7 breast cancer cells mediated by cell-specific phage fusion coat protein. Mol Pharm (2010) 0.98
Enhanced in vivo antitumor efficacy of poorly soluble PDT agent, meso-tetraphenylporphine, in PEG-PE-based tumor-targeted immunomicelles. Cancer Biol Ther (2007) 0.97
Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm (2009) 0.96
Effective stabilization and delivery of siRNA: reversible siRNA-phospholipid conjugate in nanosized mixed polymeric micelles. Bioconjug Chem (2010) 0.95
TAT peptide and its conjugates: proteolytic stability. Bioconjug Chem (2009) 0.95
Efficient intracellular drug-targeting of macrophages using stealth liposomes directed to the hemoglobin scavenger receptor CD163. J Control Release (2012) 0.95
Surface modification of liposomes with rhodamine-123-conjugated polymer results in enhanced mitochondrial targeting. J Drug Target (2011) 0.95
DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release (2003) 0.94
Polymeric micelles: polyethylene glycol-phosphatidylethanolamine (PEG-PE)-based micelles as an example. Methods Mol Biol (2010) 0.94
Surface conjugation of triphenylphosphonium to target poly(amidoamine) dendrimers to mitochondria. Biomaterials (2012) 0.94
TAT peptide-modified liposomes provide enhanced gene delivery to intracranial human brain tumor xenografts in nude mice. Oncol Res (2007) 0.94
Cell-penetrating TAT peptide in drug delivery systems: proteolytic stability requirements. Drug Deliv (2011) 0.93
Octa-arginine-modified pegylated liposomal doxorubicin: an effective treatment strategy for non-small cell lung cancer. Cancer Lett (2013) 0.93
Proteomic analysis of serum opsonins impacting biodistribution and cellular association of porous silicon microparticles. Mol Imaging (2011) 0.92
Phospholipid-polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery. Drug Deliv Transl Res (2011) 0.92
Tat peptide-mediated intracellular delivery of liposomes. Methods Enzymol (2003) 0.92
Mitochondriotropic liposomes. J Liposome Res (2005) 0.92
Mitochondria-targeted liposomes improve the apoptotic and cytotoxic action of sclareol. J Liposome Res (2010) 0.92
Stimulus-responsive nanopreparations for tumor targeting. Integr Biol (Camb) (2013) 0.91
siRNA delivery: from basics to therapeutic applications. Front Biosci (Landmark Ed) (2013) 0.91
Nanocarriers. Pharm Res (2007) 0.90
In vitro optimization of liposomal nanocarriers prepared from breast tumor cell specific phage fusion protein. J Drug Target (2011) 0.89
Tumor-specific anti-nucleosome antibody improves therapeutic efficacy of doxorubicin-loaded long-circulating liposomes against primary and metastatic tumor in mice. Mol Pharm (2009) 0.89
Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro. Eur J Pharm Biopharm (2005) 0.88
Enhanced tumor MR imaging with gadolinium-loaded polychelating polymer-containing tumor-targeted liposomes. J Magn Reson Imaging (2008) 0.88
Protective effect of coenzyme Q10-loaded liposomes on the myocardium in rabbits with an acute experimental myocardial infarction. Pharm Res (2007) 0.88
Targeting of lysosomes by liposomes modified with octadecyl-rhodamine B. J Drug Target (2011) 0.88
Improved transfection of spleen-derived antigen-presenting cells in culture using TATp-liposomes. J Control Release (2008) 0.88
Dendrosome-dendriplex inside liposomes: as a gene delivery system. J Drug Target (2011) 0.88
Multifunctionality of lipid-core micelles for drug delivery and tumour targeting. Mol Membr Biol (2010) 0.87